| World J Gastroenterol
| [0003]
|
| Anticancer Res
| [0003]
|
| Inflamm Bowel Dis
| [0003]
|
| Aliment Pharmacol Ther
| [0003]
|
| Aliment Pharmacol Ther
| [0003]
|
| Carcinogenesis
| [0006]
|
| Aliment Pharmacol Ther
| [0006]
|
| Int'' J Biochem Cell, Biol
| [0008]
|
| J Cell Biol
| [0008]
|
| Methods
| [0030]
|
| Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells
| [0039]
|
| 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint
| [0039]
|
| Molecular basis of the potential of mesalazine to prevent colorectal cancer
| [0039]
|
| Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine
| [0039]
|
| Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity
| [0039]
|
| Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cells
| [0039]
|
| Down-regulation of mu-protocadherin expression is a common event in colorectal carcinogenesis
| [0039]
|
| Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis
| [0039]
|
| Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia
| [0039]
|
| Colorectal cancer: potential therapeutic benefits of Vitamin D
| [0039]
|
| Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling
| [0039]
|
| Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
| [0039]
|